Dyadic International Inc (DYAI): Shareholders' Equity
$1.23M
As of 2025-12-31
-$2.39M
As of 2026-06-30
-51.9%
3-year compound annual growth
-46.6%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.23M | -50.1% | 2026-03-25, Balance as of period end |
| 2024-12-31 | $2.47M | -58.0% | 2026-03-25, Balance as of period end |
| 2023-12-31 | $5.88M | -47.0% | 2025-03-26, Balance as of period end |
| 2022-12-31 | $11.09M | -39.7% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $18.39M | -35.4% | 2023-03-29, Balance as of period end |
| 2020-12-31 | $28.45M | -20.7% | 2022-03-29, Balance as of period end |
| 2019-12-31 | $35.86M | -15.5% | 2021-03-30, Balance as of period end |
| 2018-12-31 | $42.45M | -15.1% | 2020-03-30, Balance as of period end |
| 2017-12-31 | $49.98M | n/a | 2019-03-27, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Dyadic International Inc (DYAI) | 2025-12-31 | $1.23M | -50.1% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | -$187.76M | n/m |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $1.92B | -0.5% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $752.60M | +2.6% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $53.55M | n/m |
| Ocugen, Inc. (OCGN) | 2025-12-31 | -$12.17M | n/m |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $120.87M | -21.1% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $3.11M | n/m |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | -$1.42M | n/m |
Compare DYAI, SRZN, CRSP, CGON side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗